Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in Europe

Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in Europe First Commercial Order by Large Lab Chain: Biomerica has received its first commercial order for Hp Detect™, from one of the largest clinical laboratory chains operating across Europe.Strategic Account: This new lab’s scale and geographic reach across Europe positions it as a reference account and potential gateway to broader EU laboratory channel adoption.Repeat Order Potential: Based on the nature of the relationship, Biomerica believes this initial or...

Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain

Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain Registration marks the Company’s entry into the UK market, where H. pylori affects an estimated 45% of the population across Europe’s five largest countries UK Market Entry: MHRA registration authorizes hp+detect™ for commercial sale in Great BritainActive Commercialization: Biomerica is in active discussions with UK partners to access the diagnostic laboratory market and expects to provide further updates as agreements are finalized.Disease Burden: The WHO designates H. pylori as a Class 1 car...

Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy

Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy Physician Interview Now Available Key Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent with the Company’s peer-reviewed randomized controlled trial.CMS Payment Rate: $300 national Medicare payment rate established, effective January 1, 2026.Physician Perspective: New intervie...

PBSV: Steady as she goes

BCLI: KOL Event Gives Overview of the use of NurOwn® in Alzheimer’s Disease; Raising Valuation to $25/Share...

MNOV: FDA Gives OK to Initiate Clinical Trial of MN-166 to Prevent ARDS in COVID- 19 Patients...